Brokers Issue Forecasts for KYMR FY2025 Earnings

Kymera Therapeutics, Inc. (NASDAQ:KYMR) – B. Riley issued their FY2025 earnings per share (EPS) estimates for Kymera Therapeutics in a note issued to investors on Monday, March 3rd. B. Riley analyst K. Patel forecasts that the company will post earnings of ($3.95) per share for the year. The consensus estimate for Kymera Therapeutics’ current full-year earnings is ($2.79) per share. B. Riley also issued estimates for Kymera Therapeutics’ FY2026 earnings at ($4.46) EPS, FY2027 earnings at ($5.62) EPS and FY2028 earnings at ($5.82) EPS.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.12). The company had revenue of $7.39 million for the quarter, compared to the consensus estimate of $14.81 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%.

A number of other equities research analysts have also weighed in on KYMR. Wells Fargo & Company upgraded Kymera Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $38.00 to $57.00 in a research report on Monday, December 2nd. BTIG Research began coverage on Kymera Therapeutics in a report on Tuesday, December 10th. They set a “buy” rating and a $60.00 price target on the stock. Stephens reiterated an “overweight” rating and issued a $60.00 price objective on shares of Kymera Therapeutics in a report on Tuesday, January 21st. Leerink Partners reiterated an “outperform” rating and set a $60.00 target price on shares of Kymera Therapeutics in a research report on Friday, December 27th. Finally, HC Wainwright upped their price target on shares of Kymera Therapeutics from $54.00 to $60.00 and gave the company a “buy” rating in a research report on Friday, February 28th. Three analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Kymera Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $56.69.

Kymera Therapeutics Stock Performance

NASDAQ KYMR opened at $32.54 on Wednesday. The firm’s fifty day moving average price is $38.23 and its two-hundred day moving average price is $43.40. The stock has a market cap of $2.11 billion, a PE ratio of -13.91 and a beta of 2.22. Kymera Therapeutics has a fifty-two week low of $29.07 and a fifty-two week high of $53.27.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Wellington Management Group LLP increased its stake in Kymera Therapeutics by 14.9% in the fourth quarter. Wellington Management Group LLP now owns 5,307,326 shares of the company’s stock valued at $213,514,000 after purchasing an additional 688,967 shares in the last quarter. Avoro Capital Advisors LLC boosted its position in shares of Kymera Therapeutics by 14.4% during the 4th quarter. Avoro Capital Advisors LLC now owns 5,150,000 shares of the company’s stock worth $207,184,000 after purchasing an additional 650,000 shares in the last quarter. Deerfield Management Company L.P. Series C acquired a new stake in shares of Kymera Therapeutics in the 4th quarter valued at about $23,856,000. Boxer Capital Management LLC bought a new stake in Kymera Therapeutics in the 4th quarter valued at about $17,098,000. Finally, Jennison Associates LLC raised its stake in Kymera Therapeutics by 85.8% during the 3rd quarter. Jennison Associates LLC now owns 797,681 shares of the company’s stock worth $37,754,000 after buying an additional 368,394 shares during the period.

Insiders Place Their Bets

In related news, CFO Bruce N. Jacobs sold 7,035 shares of the company’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $30.45, for a total transaction of $214,215.75. Following the sale, the chief financial officer now owns 201,886 shares in the company, valued at $6,147,428.70. This represents a 3.37 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Ellen Chiniara sold 2,241 shares of Kymera Therapeutics stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total value of $68,238.45. Following the completion of the sale, the insider now owns 80,085 shares of the company’s stock, valued at approximately $2,438,588.25. The trade was a 2.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 13,788 shares of company stock worth $455,202. Company insiders own 15.82% of the company’s stock.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.